BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 30115544)

  • 1. Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer.
    McKenzie HS; Mead G; Huddart R; White JD; Rustin GJS; Hennig IM; Cozens K; Cross N; Bowers M; Wheater MJ
    Clin Genitourin Cancer; 2018 Dec; 16(6):458-465.e2. PubMed ID: 30115544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
    Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
    Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
    Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
    Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors.
    Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T
    Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.
    Shiraishi T; Nakamura T; Mikami K; Takaha N; Kawauchi A; Miki T
    Int J Clin Oncol; 2009 Oct; 14(5):436-41. PubMed ID: 19856053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial.
    Mead GM; Cullen MH; Huddart R; Harper P; Rustin GJ; Cook PA; Stenning SP; Mason M;
    Br J Cancer; 2005 Jul; 93(2):178-84. PubMed ID: 15999102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.
    Kurobe M; Kawai K; Oikawa T; Ichioka D; Kandori S; Takaoka E; Kojima T; Joraku A; Suetomi T; Miyazaki J; Nishiyama H
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):127-33. PubMed ID: 25062721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer.
    Kawai K; Miyazaki J; Tsukamoto S; Hinotsu S; Hattori K; Shimazui T; Akaza H
    Jpn J Clin Oncol; 2003 Mar; 33(3):127-31. PubMed ID: 12672789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
    De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
    Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
    Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
    J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
    Farmakis D; Pectasides M; Pectasides D
    Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
    J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
    Einhorn LH; Brames MJ; Juliar B; Williams SD
    J Clin Oncol; 2007 Feb; 25(5):513-6. PubMed ID: 17290059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
    Rick O; Bokemeyer C; Beyer J; Hartmann JT; Schwella N; Kingreen D; Neureither S; Metzner B; Casper J; Wandt H; Hartmann F; Schmoll HJ; Derigs G; Gerl A; Berdel WE; Kanz L; Siegert W
    J Clin Oncol; 2001 Jan; 19(1):81-8. PubMed ID: 11134198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
    Necchi A; Nicolai N; Mariani L; Lo Vullo S; Giannatempo P; Raggi D; Farè E; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Milani A; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Feb; 12(1):63-69.e1. PubMed ID: 24161525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
    Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
    Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
    Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.
    Narayan V; Gunnarsson O; Hwang WT; Squillante CM; Nathanson KL; Stadtmauer EA; Vaughn DJ
    Clin Genitourin Cancer; 2016 Dec; 14(6):524-529. PubMed ID: 27083130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial.
    Oncol Res Treat; 2016; 39(9):553-6. PubMed ID: 27614956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.